Novo Nordisk — full event log
Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.
← back to Data by year2024· 17 events
Internal reuse of ethanol at the two largest API production sites reduces use of new ethanol by ~90%. At Kalundborg, ethanol waste and yeast slurry are turned into energy and fertiliser via the Kalundborg Symbiosis. District cooling project (operational 2026) expected to save ~400,000 m³ water/year. Wastewater treatment capacity at Kalundborg being doubled by 2026.
sustainability_report p.61
In 2024, Novo Nordisk updated its decarbonisation roadmap, setting a new target of 33% absolute scope 3 reduction by 2033 from a 2024 baseline. Covers ~70% of scope 3 in accordance with SBTi provisions, submitted for SBTi validation. Aligned with well-below 2.0°C pathway (not 1.5°C).
sustainability_report p.57
Beyond 2033, Novo Nordisk expects to use carbon removals to neutralise residual CO2e emissions of up to 10% of the baseline towards the net zero 2045 target, aligned with SBTi requirements and IPCC guidance. Exploring both nature-based and technology-based solutions for removing and storing GHG. Removals are not used to meet the 2033 scope 3 (-33%) interim target.
sustainability_report p.55
On 18 December 2024, Novo Nordisk acquired three fill-finish sites in US, Belgium and Italy from Novo Holdings A/S (via Catalent acquisition) for USD 11.7bn (DKK 82.1bn). Adds ~3,500 employees and significant manufacturing capacity. Mainly debt-financed via EUR 4.65bn Eurobond issuance.
sustainability_report p.130
Set new global target to reduce plastic footprint per patient by 30% by 2033, from baseline of 0.35 kg/patient in 2024. Achieved via reusable devices, circular design and less-frequent dosing.
sustainability_report p.14
Formalised a nature roadmap in 2024 with ambition to halt loss of nature in value chain by 2033 and achieve nature-positive status by 2045. Aligned with Kunming-Montreal Biodiversity Framework. Includes deforestation-free paper/cardboard supply chain and regenerative glucose sourcing.
sustainability_report p.68
2024 is the first year Novo Nordisk's Sustainability statement is prepared under EU Corporate Sustainability Reporting Directive (CSRD)/ESRS, with a double materiality assessment. Significantly expanded disclosure scope.
sustainability_report p.47
Deloitte provided limited assurance on the Sustainability statement under ISAE 3000 (Revised), covering ESRS compliance and EU Taxonomy disclosures.
sustainability_report p.141
Recognised by CDP among leaders on climate and water disclosure (general release 6 Feb 2025).
sustainability_report p.48
Target of zero scope 1 and 2 (market-based) CO2e emissions by 2030. ~131 ktCO2e of expected reductions identified across scope 1+2 by 2030.
sustainability_report p.57
Aspiration for minimum 45% women and 45% men in senior leadership by end of 2025. Reached 42% women in senior leadership in 2024.
sustainability_report p.87
Global target of zero landfill waste from production sites by 2030. Achieved 92% reduction vs 2019 baseline; 94 tonnes to landfill from production in 2024.
sustainability_report p.62
Since 2020, all Novo Nordisk production sites source 100% renewable electricity via a mix of Power Purchase Agreements (PPAs), Renewable Electricity Certificates (RECs), and Guarantees of Origin (GOs). Affiliates reached 99% renewable electricity coverage in 2024. Over 1,800 suppliers have committed to transitioning to renewable power as part of scope 3 decarbonisation. Steam/heat from biomass is conservatively excluded from renewable classification. Total energy from contractual renewable sources reached 54% in 2024.
sustainability_report p.56
Maintained 100% renewable electricity at production sites. Converting steam and heat in production processes to renewables by electrifying processes and covering US natural gas with biogas certificates. District cooling ring under construction at Kalundborg site (completion 2026), expected >20,000 MWh/year savings. Continuing transition away from fossil-based vehicles to BEV/PHEV.
sustainability_report p.56
Categories 1 and 2 represent ~80% of scope 3. Strategy is three-pronged: (1) converting to lower-carbon raw materials and feedstocks for devices/drugs and construction; (2) process optimisation to reduce material use; (3) requiring tier 1 suppliers to transition to renewable energy. Over 1,800 suppliers committed to renewable power. Industrial partnership for e-methanol-based lower-carbon plastic in injection devices launched in 2024.
sustainability_report p.56
Decarbonising distribution emissions across three modes: (1) air freight – converting upstream air freight to sea freight where feasible and securing Sustainable Aviation Fuel (SAF) via long-term off-take agreements; (2) sea – securing Sustainable Marine Fuel (SMF) in upstream distribution; (3) road – low-carbon road freight solutions upstream and downstream. Cat 4 fell 6% in 2024 partly due to SAF/SMF procurement curbing growth.
sustainability_report p.56
Targeting 30% reduction in plastic footprint per patient by 2033 (from 0.35 kg/patient in 2024). Converting from disposable single/multi-use pens to reusable devices (new reusable device launching 2026). Weekly basal insulin Awiqli reduces plastic ~two-thirds vs daily injection. ReMed take-back scheme for used pens operating in 7 markets (Denmark, Brazil, France, Italy, UK, Japan, Germany) with 32% return rate in Danish industry-wide scheme.
sustainability_report p.61
2023· 1 event
Scope 3 categories 1, 2, 4 and 6 restated for 2023: from 2,067/1,315/113/83 ktCO2e to 1,018/303/108/154 ktCO2e respectively. Driven by transferring contract manufacturing to activity-based accounting and updating spend-based factors. Restatement materially reduced reported scope 3.
sustainability_report p.58